UK-based Contract Research Organisation (CRO) Gentronix – a leading specialist toxicology CRO – has announced the next phase in its ongoing growth plan with the opening of a brand-new 2,819 sq ft laboratory and office suite at Alderley Park.

The newly established suite will accommodate the activities of the Big Blue® transgenic rodent mutation workflow, increasing capacity in this in-demand mutagenesis toxicology test and growing the Gentronix footprint at Alderley Park by 30%.

This continued growth follows a successful 2300 sq ft. expansion in 2021 to increase capacity of genetic, ocular and skin toxicology testing in 2021.

Gentronix completed the acquisition of the Big Blue® transgenic rodent mutation assays in June 2021 and have subsequently undertaken an extensive proficiency exercise prior to conducting client studies. Now with an established service to support GLP client studies, market demand is high. This additional space within the Gentronix GLP footprint will bring increased capacity to the global marketplace for transgenic rodent mutation services.

The Big Blue® mutation assay plays a key role in enabling risk assessments for materials where pre-existing data indicates a potential mutagenicity risk to human health and the environment.

As well as increasing the service capacity for the Big Blue® transgenic rodent mutation assays, the growth in footprint also allows Gentronix to expand capacity for its core genetic, skin and ocular toxicology services and accommodate new services in the near future.

CEO at Gentronix, Matt Tate, said:

“We are delighted to be expanding our footprint within the Alderley Park Campus once again which has also allowed us to create more jobs for highly skilled scientists in the North West. This further expansion is an important part of our continued growth plan and will allow us to increase capacity to meet continuing market demands. We are able to support our clients with their genetic toxicology testing right from early-stage screening tests through to regulatory studies enabling human risk assessment.”

As a leading predictive toxicology CRO, operating from its GLP laboratory base at Alderley Park, Gentronix’s work helps develop safe products used by millions of people around the world including pharmaceuticals, agrochemicals, fragrances, foods, flavours, personal care products and cosmetics.